Companies
Wefunder
hosted live 2026 Reg CF campaigns for companies including Mahzi Therapeutics (gene therapy for Pitt Hopkins Syndrome and related rare neurodevelopmental disorders) and Eliaz Therapeutics (its XGal-3 apheresis device targeting sepsis via Galectin-3 removal).
- Country
- United States
reg-cf
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| finance-investment | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $60 million total prior capital raised from venture capital investors | biobase.whitefordresearch.com · kingscrowd.com · thenyledger.com |
| Funding | $16 million in cumulative grant awards from the California Institute for Regenerative Medicine (CIRM) | biobase.whitefordresearch.com · kingscrowd.com · thenyledger.com |
| Funding | 2026 Regulation Crowdfunding (Reg CF) offering on Wefunder with a target of $50,000 and a maximum of $1.2 million | biobase.whitefordresearch.com · kingscrowd.com · wefunder.com |
| Headcount | 14 to 17 employees | kingscrowd.com |
| Revenue | $0 as of fiscal year 2025 | kingscrowd.com |
| Regulatory approval | FDA Orphan Drug Designation, Fast Track Designation, and Rare Pediatric Disease Designation for MZ-1866 | biopharminternational.com · prnewswire.com |
Independent sources: biobase.whitefordresearch.com · biopharminternational.com · kingscrowd.com · prnewswire.com · thenyledger.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Crowdfunding & retail investment in biotech | finance-investment | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.